Previous 10 | Next 10 |
Biotech stocks are stocks of companies that are involved in the research and development of new drugs, medical devices, and other health-related technologies. Biotech investors like these stocks for many reasons, but most importantly because they offer the potential for high growth. The adv...
Aflibercept 8 mg Positive Pivotal Results in Diabetic Macular Edema and Wet Age-Related Macular Degeneration Presented at AAO PR Newswire PHOTON and PULSAR data presentations demonstrate aflibercept 8 mg led to sustained improvements in vision and anatomic measures...
Summary In this article, I explain how I generate ideas and my methodology of adding companies to my watchlist. I also discuss certain areas of my watchlist, including merger arbitrage, semiconductor equipment, and defense contractors. I showcase my entire watchlist and discus...
The FDA has approved Dupixent, developed by Regeneron ( NASDAQ: REGN ) and Sanofi ( NASDAQ: SNY ) ( OTCPK:SNYNF ) ( GCVRX ), for adults with prurigo nodularis, a chronic, inflammatory skin condition. The subcutaneously administered treatment is already indi...
Dupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis PR Newswire Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trials About 7...
Summary The stock is down 80% year-to-date due to disappointing study results from the company’s two lead product candidates, CBP-201 and CBP-307. CBP-307 development has been put on ice. But CBP-201 is back, and if more successful this time, it could be on a fast track...
The following slide deck was published by Regeneron Pharmaceuticals, Inc. in conjunction with this event. For further details see: Regeneron Pharmaceuticals (REGN) Investor Presentation- Slideshow
Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis PR Newswire Interim data from the cardiomyopathy arm of the Phase 1 s...
Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet PR Newswire Dupixent is the first and only biologic that significantly improved skin clearance, and reduced itch and ...
The following slide deck was published by Regeneron Pharmaceuticals, Inc. in conjunction with this event. For further details see: Regeneron Pharmaceuticals (REGN) Presents at the ESMO Congress 2022 - Slideshow
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...